Company Overview and News

 
Hong Kong’s Hang Lung Properties sees 2017 underlying profit fall on declining China mall rental income

2018-01-30 scmp
Including a revaluation gain, net profit rose 31 per cent, and the developer expresses confidence in its outlook

 
Ronnie C. Chan, The Buffett Of Hong Kong: Thoughts On Global Economic Futures

2017-10-02 seekingalpha
John Sheehy of Konecko recently highlighted the writings of Ronnie Chan, Board Chairman of the Hang Lung Group (OTCPK:HNLGF). Hang Lung is one of Hong Kong’s largest real estate developers. Sheehy noted that Chan (like Buffett) has a reputation for writing insightful shareholder letters. I quote Sheehy: “Chan has a reputation for thinking long-term. The company completed its Harbourside luxury apartment tower in Hong Kong in 2004 and held many units off the market until selling them in 2014 and realizing a 78% gross margin due to market appreciation.

 
Mixed reaction to latest measures to cool Hong Kong property market

2017-05-22 scmp
HK Monetary Authority tells lenders to put greater weighing on assessment of credit worthiness, while cutting amount of allowable loans on residential and commercial properties

 
Half-year Report

2017-04-26 londonstockexchange
Edinburgh Dragon Trust's objective is long-term capital growth through investment in Asia, with the exception of Japan and Australasia.  Investments are made primarily in stock markets in the region, principally in large companies.  When appropriate, the Company will utilise gearing to maximise long term returns.

 
Hang Lung Properties’ 2016 core profit up 45pc to HK$6.3bn

2017-01-26 scmp
Hang Lung Properties, the first developer to kick off the reporting season, reported strong earnings last year on the back of rising property income in Hong Kong.

 
Wall Street is missing a Chinese consumer boom - Business Insider

2017-01-12 businessinsider
China is home to plenty of paradoxes, but some of them are Western misconceptions. For example, notion of "ghost cities" is largely the result of information inefficiencies and misunderstandings related to China’s development model. The ghost city theme was initially started by Western journalists unprepared to see the scale of construction sites in China. Some of them didn’t even go to China, instead using satellite images.

 
Growing wealth and doing good can co-exist, says former property tycoon’s heiress

2017-01-06 scmp
Applying environmental, social and governance principles when creating an investment portfolio is alien to most people in Hong Kong – but the practice has a strong following elsewhere

 
Annual Financial Report

2016-11-03 londonstockexchange
Edinburgh Dragon Trust's objective is long-term capital growth through investment in the Asia Pacific region (with the exception of Japan and Australasia).  Investments are made mainly in stock markets in the region, principally in large companies.  When appropriate the Company will utilise gearing to maximise long term returns.

 
Hang Lung opens giant new Dalian mall at its “most difficult time” in 20 years

2016-09-12 scmp
The 7 billion yuan, 220,000 sq m Olympia 66 is firm’s largest yet in the mainland

 
Tweedy Browne Fund 2Q16 Commentary - ValueWalk

2016-08-03 valuewalk
Having regained their footing in mid-February, global equity markets continued to advance during the 2nd quarter right up until the Brexit vote in late June. Despite the turbulence produced by the surprise vote, it was not enough to erase what turned out to be a modestly positive quarter in terms of returns. We are pleased to report that all four of the Tweedy Browne funds finished the quarter in positive territory, and well ahead of their respective benchmark indices.

 
Hang Lung’s strong HK sales cancelled out by weak mainland rentals

2016-07-28 scmp
Hang Lung Properties, one of Hong Kong’s leading developers, delivered first-half profits in line with market expectations, as strong residential sales in Hong Kong were cancelled out by weakened rental income in mainland China.

 
Hong Kong and mainland China shares close morning lower as investors worry over market uncertainties

2016-07-27 scmp
Hang Seng Index opens up 0.29 per cent or 63.58 points at 22,193.31, while Hang Seng China Enterprises index is up 0.5 per cent or 45.64 points to 9,107.89

 
Hong Kong and mainland China shares open higher as investors bet on improved earnings results

2016-07-27 scmp
Hang Seng Index opens up 0.29 per cent or 63.58 points at 22,193.31, while Hang Seng China Enterprises index is up 0.5 per cent or 45.64 points to 9,107.89

 
China Markets Live - Hong Kong’s Hang Seng sinks below 19,000 for first time since 2012

2016-01-20 scmp
Hong Kong dollar plunges amid continued capital outflows; speculations grow that the city may abandon the US dollar peg

 
China Markets Live - Hong Kong’s Hang Seng ends below 19,000 for first time since 2012

2016-01-20 scmp
Hong Kong dollar plunges amid continued capital outflows; speculations grow that the city may abandon the US dollar peg

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...